Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.

摘要

Among second-line TKI-treated CML patients, dasatinib patients had significantly higher adherence and lower discontinuation rates compared with patients receiving second-line nilotinib.